May 11, 2021 / 01:30PM GMT
Geoffrey Christopher Meacham - BofA Securities, Research Division - Research Analyst
Okay, good morning. Welcome to the first day of the BofA Virtual Vegas Healthcare Conference. My name is Geoff Meacham. I'm the senior biopharma analyst here. And I have Alec from my team with me on video as well.
we're thrilled to have with us Lilly. And speaking on behalf of Lilly, we have Mike Mason, Senior Vice President, Lilly Diabetes. Mike, thanks for coming.
Michael B. Mason - Eli Lilly and Company - Senior VP & President of Lilly Diabetes
Thanks. It's great to be here. I appreciate everyone's interest in Lilly Diabetes.
Questions and Answers:
Geoffrey Christopher Meacham - BofA Securities, Research Division - Research AnalystRight. So we're going to do some questions here between Alec and I, and let's get right into it. So Mike, when you think about what happened last year with COVID and you guys had a really good first quarter, just help walk us through kind of the first quarter of 2021. Coming out of